You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. A CD8+ T cell diagnostic to identify children with pulmonary tuberculosis

    SBC: ViTi, Inc            Topic: NIAID

    DESCRIPTION provided by applicant Tuberculosis TB disease which results from infection with Mycobacterium tuberculosis Mtb is a leading cause of infectious morbidity and mortality in children andlt years old worldwide In TB endemic regions in which the vast majority of the worldandapos s annual million adult cases of TB disease reside children andlt years old account for ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Conformable Thermal Ground Plane

    SBC: i2C Solutions, LLC            Topic: DTRA122002

    Miniaturized smart munitions are seeing increasing use across all branches of the Department of Defense (DoD) in order to meet the ever evolving mission needs for the U.S. warfighter. These smart micromuntions have been enabled by advances in capabilities and miniaturization of critical microelectonic and microelectromechanical systems such as sensor, navigational, communications, and triggering ...

    SBIR Phase I 2013 Department of DefenseDefense Threat Reduction Agency
  4. Optically Covert Detection of Trace WMD Residues

    SBC: TDA Research, Inc.            Topic: DTRA122003

    It is challenging to detect CBRN weapons production facilities that are hidden in residential and industrial neighborhoods. Once the weapons are manufactured, they will be sealed and removed from the site of production, so developing techniques to reveal the presence of the weapons will likely be fruitless. In this project, we will develop indicators that can be applied covertly around suspect a ...

    SBIR Phase I 2013 Department of DefenseDefense Threat Reduction Agency
  5. Real-Time Frequency-Selective Fading Channel Realization Generator

    SBC: Welkin Sciences, LLC            Topic: DTRA122020

    Welkin Sciences proposes to develop two run-time channel realization generators that are functionally equivalent to DTRAs ACIRF code. One is a software only implementation suitable for computer link simulations and test analysis applications. The other is a combination of software and FPGA-based firmware that can be embedded into existing and future hardware-in-the-loop (HWIL) fading channel simul ...

    SBIR Phase I 2013 Department of DefenseDefense Threat Reduction Agency
  6. Covert Optically-Reporting Threat-Functionalized Nanomaterials

    SBC: VOXTEL, INC.            Topic: DTRA122003

    The Defense Threat Reduction Agency (DTRA) and the U.S. Strategic Command Center for Combating Weapons of Mass Destruction (SCC-WMD) requires transformational materials technology to support the intelligence, surveillance, and reconnaissance (ISR) of personnel and materials associated with weapons of mass destruction (WMD) development, manufacturing, and proliferation. Voxtel, Inc. proposes to fa ...

    SBIR Phase I 2013 Department of DefenseDefense Threat Reduction Agency
  7. A Synthetic Human Cytomegalovirus Vaccine Platform

    SBC: TOMEGAVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government